NCT02632448 2025-05-02A Study of LY2880070 in Participants With Advanced or Metastatic CancerEsperas Pharma Inc.Phase 1/2 Completed229 enrolled
NCT02393248 2023-01-06Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)Incyte CorporationPhase 1/2 Terminated201 enrolled 71 charts